Involvement of CKS1B in the anti-inflammatory effects of cannabidiol in experimental stroke models

Chen, Kechun; Xu, Bingtian; Xiao, Xuan; Long, Lu; Zhao, Qian; Fang, Zicen; Tu, Xingxing; Wang, Jiakang; Xu, Jiangping; Wang, Haitao

doi:10.1016/j.expneurol.2023.114654

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, some reports have shown cellular protection after OGD exposure by pretreating cells with CBD at even lower doses (from 0.1 to 1 μM). 35 , 36 Interestingly, our results showed a great performance of the NPCBD in restoring PCC viability after an OGD insult, even at 0.01 mg/mL doses (corresponding to 0.2 μM), exhibiting great therapeutic potential.…”

Section: Resultsmentioning

confidence: 65%

“…The effect of NPCBD on OGD-related inflammation is consistent with many previous studies using CBD in classical formulations. 13 , 26 , 35 , 36 Neuroinflammation is pivotal in secondary injury after cerebral ischemia-induced brain injury. Thus, a reduction in the main pro-inflammatory cytokines and chemokines after the treatment with NPCBD proves its potential as a new CBD formulation to ameliorate ischemic-related inflammatory processes in the CNS.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, some reports have shown cellular protection after OGD exposure by pretreating cells with CBD at even lower doses (from 0.1 to 1 μM). 35,36 PCC viability after an OGD insult, even at 0.01 mg/mL doses (corresponding to 0.2 μM), exhibiting great therapeutic potential.…”

Section: Npcbd Ameliorated Ogd-induced Cytotoxicitymentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain

Chevalier,

Al-Waeel,

Alsharabasy

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Cannabidiol (CBD) is the most relevant nonpsychostimulant phytocompound found in Cannabis sativa. CBD has been extensively studied and has been proposed as a therapeutic candidate for neuroinflammation-related conditions. However, being a highly lipophilic drug, it has several drawbacks for pharmaceutical use, including low solubility and high permeability. Synthetic polymers can be used as drug delivery systems to improve CBD's stability, half-life, and biodistribution. Here, we propose using a synthetic polymer as a nanoparticulate vehicle for CBD (NPCBD) to overcome the pharmacological drawbacks of free drugs. We tested the NPCBDengineered system in the context of ischemic events in a relevant oxygen and glucose deprivation (OGD) model in primary cortical cells (PCC). Moreover, we have characterized the inflammatory response of relevant cell types, such as THP-1 (human monocytes), HMC3 (human microglia), and PCC, to NPCBD and observed a shift in the inflammatory state of the treated cells after the ischemic event. In addition, NPCBD exhibited a promising ability to restore mitochondrial function after OGD insult in both HMC3 and PCC cells at low doses of 1 and 0.2 μM CBD. Taken together, these results suggest the potential for preclinical use.

show abstract

Section: Resultsmentioning

confidence: 65%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain

Chevalier,

Al-Waeel,

Alsharabasy

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

Aquaporin 4 and the endocannabinoid system: a potential therapeutic target in brain injury

Martínez-Torres,

Morán

2024

Exp Brain Res

View full text Add to dashboard Cite

Brain edema is a critical complication arising from stroke and traumatic brain injury (TBI) with an important impact on patient recovery and can lead to long-term consequences. Therapeutic options to reduce edema progression are limited with variable patient outcomes. Aquaporin 4 (AQP4) is a water channel that allows bidirectional water diffusion across the astrocyte membrane and participates in the distinct phases of cerebral edema. The absence or inhibition of this channel has been demonstrated to ameliorate edema and brain damage. The endocannabinoid system (ECS) is a neuromodulator system with a wide expression in the brain and its activation has shown neuroprotective properties in diverse models of neuronal damage. This review describes and discusses the major features of ECS and AQP4 and their role during brain damage, observing that ECS stimulation reduces edema and injury size in diverse models of brain damage, however, the relationship between AQP4 expression and dynamics and ECS activation remains unclear. The research on these topics holds promising therapeutic implications for the treatment of brain edema following stroke and TBI.

show abstract

Microglia-driven neuroinflammation: A pivotal player in brain disorders

Vale,

Bernardino

2025

Brain and Organ Communication

View full text Add to dashboard Cite

Involvement of CKS1B in the anti-inflammatory effects of cannabidiol in experimental stroke models

Cited by 4 publications

References 35 publications

Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain

Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain

Aquaporin 4 and the endocannabinoid system: a potential therapeutic target in brain injury

Microglia-driven neuroinflammation: A pivotal player in brain disorders

Contact Info

Product

Resources

About